Varex Imaging Corporation designs, manufactures, and sells X-ray imaging components. It operates through two segments, Medical and Industrial. The Medical segment designs, manufactures, sells, and services X-ray imaging components, comprising X-ray tubes, digital detectors and accessories, ionization chambers, high voltage connectors, image-processing software and workstations, 3D reconstruction software, computer-aided diagnostic software, collimators, automatic exposure control devices, generators, and heat exchangers. This segment's products are used in a range of applications, including CT, mammography, oncology, cardiac, surgery, dental, and other diagnostic radiography uses. The Industrial segment designs, develops, manufactures, sells, and services Linatron X-ray linear accelerators, non-intrusive cargo inspection systems, X-ray tubes, digital detectors, high voltage connectors, and coolers for use in security and inspection applications, such as baggage screening at airports, cargo screening at ports and borders, and nondestructive testing, irradiation, and inspection in various applications. It sells its products through imaging system original equipment manufacturers, independent service companies, and distributors, as well as directly to end-users. The company has operations in North America, Latin America, Europe, the Middle East, India, Africa, Asia, and Australia. The company was incorporated in 2016 and is headquartered in Salt Lake City, Utah.…
Varex Imaging Shareholders Approve Teledyne Merger Agreement
Varex Imaging (NASDAQ: VREX) is listed on Nasdaq, where its shares trade in USD. It belongs to the Medical Devices industry, part of the Healthcare sector, and reports about 2,500 employees.
The shares were at 18.10 USD on 20 November 2026, up 52.2% over 52 weeks. Its 52-week range is 9.090 USD to 18.63 USD: the price is 2.8% below the high and 99.1% above the low.
At a market capitalisation of 768.59M USD, it trades at 34.2 times trailing earnings and 16.9 times forward earnings. The median trailing P/E of its 19 largest Medical Devices peers is 25.5, a premium of 34% for VREX.
Varex Imaging reports return on equity of -14.9%, an operating margin of 8.3% and revenue up 3.7% year over year.
Its debt exceeds its cash by 279.20M USD, a debt-to-equity ratio of 0.84. Its Piotroski F-score is 6 out of 9, an average reading of its financial health. 2 analysts cover the stock; their mean price target of 18.90 USD is 4.4% above the current price. The next earnings report is expected on 1 December 2026.